NCT07667101 Hepatitis C Pharmacist, Physician, Patient Navigator Collaborative Care Model in Permanent Supportive Housing
| NCT ID | NCT07667101 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Washington |
| Condition | HEPATITIS C (HCV) |
| Study Type | INTERVENTIONAL |
| Enrollment | 444 participants |
| Start Date | 2026-06-01 |
| Primary Completion | 2028-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 444 participants in total. It began in 2026-06-01 with a primary completion date of 2028-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of this study is to extend our prior research by conducting a pragmatic implementation trial using a parallel-group, cluster randomized design to evaluate the PPP-CCM's ability to improve access to DAAs for HCV within a network of permanent supportive housing (PSH) buildings in Seattle and King County. The study will implement PPP-CCM to 16 housing buildings, randomizing half to receive PPP-CCM (intervention) versus usual care (UC) for 12-months, after which all buildings will have access to PPP-CCM. All buildings will have access to point-of-care HCV screening for the first 6 months of the study. Study outcome data will be collected through a longitudinal cohort-study of persons who screened positive for HCV which will conduct surveys and review of medical records at baseline, 12- and 24-months.
Eligibility Criteria
Inclusion Criteria: * Adult ≥18 years of age * Currently a resident at one of DESC's PSH buildings at the time of study enrollment * Positive HCV test documented (screening antibody test or viral load test) * Provides release of information (ROI) to access community pharmacy electronic medical records (EHR) and/or other HCV treatment providers for information on HCV care during the study period between baseline visit and 24-month visit Exclusion Criteria: * Taking medications to treat HCV at the start of the study * Cognitive impairment (acute or chronic) resulting in inability to provide informed consent * Currently or impending incarceration * People who plan to leave the Seattle area within 24 months * Not English speaking * Behavioral risk posing safety concerns per discretion of research staff
Contact & Investigator
Judith Tsui, MD, MPH
PRINCIPAL INVESTIGATOR
University of Washington
Frequently Asked Questions
Who can join the NCT07667101 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying HEPATITIS C (HCV). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07667101 currently recruiting?
Yes, NCT07667101 is actively recruiting participants. Contact the research team at kennedev@uw.edu for enrollment information.
Where is the NCT07667101 trial being conducted?
This trial is being conducted at Seattle, United States.
Who is sponsoring the NCT07667101 clinical trial?
NCT07667101 is sponsored by University of Washington. The principal investigator is Judith Tsui, MD, MPH at University of Washington. The trial plans to enroll 444 participants.